ACASTI PHARMA INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.705 USD | -2.00% |
|
-2.00% | -6.41% |
| Feb. 12 | Acasti Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 | CI |
| Feb. 07 | Craig-Hallum Initiates Acasti Pharma With Buy Rating, $6 Price Target | MT |
Evolution of the average Target Price on Acasti Pharma Inc.
Price target over the last 5 years
History of analyst recommendation changes
35e05.xDbZDYPQqellvs7aDaV03puAQcdgJJxBMqfJP9QJkck.rFmKXreIz9BU5IapOcQzjuPPL4lQQeUwRPKuUbBgyKPzUqNvyeTMmjLf_g~388890c045ef675002072f93e18da1fe
Analysts' Consensus
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
3.758
CAD
Average target price
8.063
CAD
Spread / Average Target
+114.57%
High Price Target
8.063
CAD
Spread / Highest target
+114.57%
Low Price Target
8.063
CAD
Spread / Lowest Target
+114.57%
Consensus detail
Consensus revision (last 18 months)
Analysts covering Acasti Pharma Inc.
| Craig-Hallum |
EPS Revisions
- Stock Market
- Equities
- ACST Stock
- Consensus Acasti Pharma Inc.